We target diseases in premature infants or caused by antibiotic-resistant bacteria
Latest press releases
2026-07-07 12:05
Infant Bacterial Therapeutics CFO Leaves the Company
2026-05-07 17:15
Annual General Meeting of Infant Bacterial Therapeutics
Subscribe to our press releases
Research and Development
IBT is a pharmaceutical company whose purpose is to develop and market medicines for diseases affecting premature infants.
IBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in breast milk. IBP-9414 is expected to be the first product in the new class of biological medicines called "Live Biotherapeutic Products" for premature infants. The development of IBP-9414 is currently in its final phase. The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122.
Read MoreIBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in breast milk. IBP-9414 is expected to be the first product in the new class of biological medicines called "Live Biotherapeutic Products" for premature infants. The development of IBP-9414 is currently in its final phase. The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122.
Calendar
Interim report Q3 July–September 2026 - November 13, 2026
Year-end report 2026 - 11 February 2027
Annual report - March 2027
Interim report Q1 January-March 2027, 4 May 2027
Annual General Meeting 2027, 5 May 2027
Interim report Q2 April-June 2027 , 27 August 2027
Read MoreYear-end report 2026 - 11 February 2027
Annual report - March 2027
Interim report Q1 January-March 2027, 4 May 2027
Annual General Meeting 2027, 5 May 2027
Interim report Q2 April-June 2027 , 27 August 2027